• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Paroxetine does not improve left ventricle ejection fraction at 12 weeks post-anterior myocardial infarction

byMeagan WiedermanandMichael Pratte
November 8, 2021
in Cardiology, Emergency, Imaging and Intervention
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Paroxetine’s G-protein receptor kinase 2 inhibitory activity was not shown to alter anterior myocardial infarction left ventricle ejection fraction, left ventricular end-diastolic diameter, or end-systolic diameter, but improved late gadolinium enhancement compared to a placebo group at 12 weeks after anterior myocardial infarction.

2. Paroxetine was not found to significantly alter mortality or adverse effects compared to placebo.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Remodeling after myocardial infarction (MI) involves scar formation, ventricular dilation, and deterioration of contractile functions. This is signaled by intracellular signals including G-protein receptor kinases (GRK). Preclinical studies have demonstrated that inhibiting GRK2 may attenuate maladaptive responses. This study investigated the efficacy of paroxetine, a selective serotonin reuptake inhibitor that also inhibits GRK2, at reducing left ventricular cardiac remodeling, measured as change in left ventricular ejection fraction (LVEF) from baseline to 12 weeks using imaging in MI patients. This study also measured change in left ventricular end-diastolic and end-systolic volumes and change in late gadolinium enhancement. Patients randomized into paroxetine or placebo were comparable for their time to treat their MI. While LVEF improved between post-MI and 12 weeks, the paroxetine group did not improve more than the control group. Similarly, the paroxetine and control group did not differ on how patients improved on left ventricular end-diastolic diameter, or end-systolic diameter, echocardiograms findings, or mortality. The treatment group did, however, have improved late gadolinium enhancement percentage compared to the control group. This study was limited by being significantly underpowered due to higher attrition (24%) than anticipated (10%) in the power calculation. Additionally, participants had only moderate levels of LVEF reduction which limited the sensitivity of the study to detect differences based on treatment.

Click to read the study in JAMA Cardiology

Relevant Reading: Hypothesis: Paroxetine, a G Protein-Coupled Receptor Kinase 2 (GRK2) Inhibitor Reduces Morbidity and Mortality in Patients With Heart Failure

In-Depth [randomized controlled trial]: This study was an analysis of data from the Paroxetine-Mediated GRK2 Inhibition to reduce cardiac remodeling after acute myocardial infarction (CARE-AMI) double-blind, randomized controlled trial. Participants had MI with LVEF of ≤45% received either 20 mg paroxetine (measured at 12 weeks) or placebo in addition to guideline-directed medical treatment. Randomization was done using sequential boxes. Left ventricular ejection fraction was assessed at baseline and 12 weeks via transthoracic echocardiography and magnetic resonance imaging. 50 anterior wall MI patients (age = 62±13 years, 82% men) were eligible to undergo randomization and 38 completed the imaging (the subset of whom did not differ on any patient characteristics compared to the whole sample). Importantly, the randomized groups were comparable on door-to-balloon time and symptom onset to balloon inflation time. LVEF improved from baseline to 12 weeks treatment in both the paroxetine (4.0±7.0%) and control (6.3±6.3%) groups, however, the treatment did not significantly improve LVEF compared to the control group (-2.4%, 95% CI = -6.8% to 2 .1%]; P = 0.29). The treatment and control group did not differ on improvement from baseline to 12 weeks treatment in terms of left ventricular end-diastolic diameter (-0.2mm, 95% CI = -4.8 to 4.3; P = 0.92) or end-systolic diameter (3.6 mm, 95% CI = -1.7 to 8.8; P = 0.18). Late gadolinium enhancement significantly decreased more in the experimental group (-13.6±12.9%) compared with the control group (-4.5±9.5%) (-9.1%, 95% CI = -16.6% to -1.6%; P = 0.02). Echocardiograms at follow-up were comparable between the experimental and control group. As none of the participants died during the trial, there was no mortality difference between the experimental and control group.

RELATED REPORTS

Bivalirudin during and post-percutaneous coronary intervention reduces bleeding and mortality compared to heparin monotherapy

Personalized cooler dialysate does not reduce cardiovascular events for hemodialysis patients

Contemporary pattern of treatment time and in-hospital mortality among US patients with ST-segment elevation myocardial infarction between 2018-2021

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: acute myocardial infarctionHeart Attack (Myocardial Infarction)LV ejection fractionmyocardial infarctionparoxetine
Previous Post

Intranasal oxytocin showed no benefits for pediatric autism spectrum disorder

Next Post

Predicted long-term effects of dapagliflozin in heart failure suggest association with improved event-free survival

RelatedReports

Appropriate use criteria for angiography may frequently miss obstructive coronary artery disease
Cardiology

Bivalirudin during and post-percutaneous coronary intervention reduces bleeding and mortality compared to heparin monotherapy

December 6, 2022
Fish oil and aspirin did not reduce arteriovenous fistula failure: The FAVOURED trail
Cardiology

Personalized cooler dialysate does not reduce cardiovascular events for hemodialysis patients

November 23, 2022
Propofol appears safe and effective in procedural sedation for cardioversion
Cardiology

Contemporary pattern of treatment time and in-hospital mortality among US patients with ST-segment elevation myocardial infarction between 2018-2021

November 9, 2022
Prevalence of hypertension among adolescents varies by race and BMI
Cardiology

Timing of daily antihypertensives does not change cardiovascular outcomes

November 1, 2022
Next Post
Long-term outcomes for off-pump and on-pump CABG are similar

Predicted long-term effects of dapagliflozin in heart failure suggest association with improved event-free survival

Diabetic ketoacidosis not associated with poor long-term metabolic control in children

Similarities noted in pediatric Medicaid emergency and urgent care visits

Intranasal surfactant does not improve outcomes for children with acute otitis media

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Chronic obstructive pulmonary disease associated with worse postoperative outcomes
  • Empagliflozin use is associated with slower progression of chronic kidney disease
  • Diagnostic tool may help identify cerebral palsy regardless of encephalopathy features
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options